Literature DB >> 12794142

OX40 ligation on activated T cells enhances the control of Cryptococcus neoformans and reduces pulmonary eosinophilia.

Ian R Humphreys1, Lorna Edwards, Gerhard Walzl, Aaron J Rae, Gordon Dougan, Sue Hill, Tracy Hussell.   

Abstract

Pulmonary eosinophilia induced in C57BL/6 mice after Cryptococcus neoformans infection is driven by CD4(+) Th2 cells. The immunological mechanisms that protect against eosinophilia are not fully understood. Interaction of OX40 (CD134) and its ligand, OX40L, has been implicated in T cell activation and cell migration. Unlike CD28, OX40 is only expressed on T cells 1-2 days after Ag activation. Manipulation of this pathway would therefore target recently activated T cells, leaving the naive repertoire unaffected. In this study, we show that engagement of OX40 by an OX40L:Ig fusion protein drives IFN-gamma production by CD4(+) T cells and reduces eosinophilia and C. neoformans burden in the lung. Using gene-depleted mice, we show that reduction of eosinophilia and pathogen burden requires IL-12 and/or IFN-gamma. C. neoformans infection itself only partially induces OX40L expression by APCs. Provision of exogenous OX40L reveals a critical role of this pathway in the prevention of C. neoformans-induced eosinophilia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12794142     DOI: 10.4049/jimmunol.170.12.6125

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

Review 1.  Into the eye of the cytokine storm.

Authors:  Jennifer R Tisoncik; Marcus J Korth; Cameron P Simmons; Jeremy Farrar; Thomas R Martin; Michael G Katze
Journal:  Microbiol Mol Biol Rev       Date:  2012-03       Impact factor: 11.056

2.  Phenotypic and functional characterization of vaginal dendritic cells in a rat model of Candida albicans vaginitis.

Authors:  Flavia De Bernardis; Roberta Lucciarini; Maria Boccanera; Consuelo Amantini; Silvia Arancia; Stefania Morrone; Michela Mosca; Antonio Cassone; Giorgio Santoni
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

3.  CD8 T cells modulate CD4 T-cell and eosinophil-mediated pulmonary pathology in pneumocystis pneumonia in B-cell-deficient mice.

Authors:  Steve D Swain; Nicole N Meissner; Allen G Harmsen
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

Review 4.  Immune response and immunotherapy to Cryptococcus infections.

Authors:  Qing Zhou; William J Murphy
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 5.  Innate host defenses against Cryptococcus neoformans.

Authors:  Camaron Hole; Floyd L Wormley
Journal:  J Microbiol       Date:  2016-02-27       Impact factor: 3.422

6.  IL-23 dampens the allergic response to Cryptococcus neoformans through IL-17-independent and -dependent mechanisms.

Authors:  Wendy A Szymczak; Rani S Sellers; Liise-anne Pirofski
Journal:  Am J Pathol       Date:  2012-02-16       Impact factor: 4.307

7.  Anti-PD-1 Antibody Treatment Promotes Clearance of Persistent Cryptococcal Lung Infection in Mice.

Authors:  Jonathan A Roussey; Steven P Viglianti; Seagal Teitz-Tennenbaum; Michal A Olszewski; John J Osterholzer
Journal:  J Immunol       Date:  2017-10-16       Impact factor: 5.422

8.  OX40 interactions in gastrointestinal nematode infection.

Authors:  Michelle X Ierna; Hannah E Scales; Herbert Schwarz; Campbell Bunce; Anne McIlgorm; Paul Garside; Catherine E Lawrence
Journal:  Immunology       Date:  2006-01       Impact factor: 7.397

9.  Interleukin-17A enhances host defense against cryptococcal lung infection through effects mediated by leukocyte recruitment, activation, and gamma interferon production.

Authors:  Benjamin J Murdock; Gary B Huffnagle; Michal A Olszewski; John J Osterholzer
Journal:  Infect Immun       Date:  2013-12-09       Impact factor: 3.441

10.  OX40 costimulation prevents allograft acceptance induced by CD40-CD40L blockade.

Authors:  Bryna E Burrell; Guanyi Lu; Xian C Li; D Keith Bishop
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.